Pages that link to "Q37599740"

The following pages link to Mutational activation of the c-K-ras gene in human pancreatic carcinoma. (Q37599740):

Displaying 24 items.

• Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients (Q21328691) (← links)
• Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis (Q30277400) (← links)
• Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer (Q30410012) (← links)
• Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib (Q30422319) (← links)
• Molecular technology and pancreatic cancer (Q31800438) (← links)
• Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. (Q34446262) (← links)
• Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis. (Q34547888) (← links)
• Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors (Q35034152) (← links)
• Recent results in animal models of pancreatic carcinoma: histogenesis of tumors (Q35241617) (← links)
• K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines (Q35782168) (← links)
• Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations. (Q35839323) (← links)
• Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour (Q36053653) (← links)
• Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM) (Q37154124) (← links)
• Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues (Q38418916) (← links)
• Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. (Q38488416) (← links)
• Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. (Q40837209) (← links)
• The Use of Molecular Technology in the Differentiation of Pancreatic Cancer and Chronic Pancreatitis (Q40855140) (← links)
• Contributions of the molecular biologist in gastrointestinal cancer and precancer screening: current possibilities and future prospects. (Q40916028) (← links)
• Diagnostic detection of mutant ras genes in minor cell populations (Q40924217) (← links)
• K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines (Q41437472) (← links)
• Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas (Q46265264) (← links)
• Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. (Q53439727) (← links)
• Ki-ras oncogene activation in preinvasive pancreatic cancer (Q67485492) (← links)
• Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts (Q72575174) (← links)